Lake Street analyst Frank Takkinen lowered the firm’s price target on Inotiv (NOTV) to $5 from $6 and keeps a Buy rating on the shares. Inotiv’s recovery “continues to trend favorably,” but the firm is taking a more conservative stance with its revenue and EBITDA estimates as it now believes its prior view of the recovery ramp was “too steep,” the analyst tells investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NOTV:
- Inotiv, Inc. Reports Improved Q2 Fiscal 2025 Results
- Inotiv, Inc. (NOTV) Q2 Earnings Cheat Sheet
- Lake Street doesn’t expect Inotiv financial impact from FDA ‘headline noise’
- Inotiv drops after FDA says phasing out animal testing of monoclonal antibodies
- Sea Pharmaceuticals announces strategic relationship with Inotiv